Literature DB >> 33643033

Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.

Zhihong Zuo1,2, Ting Wu1,3, Liangyu Pan1, Chenzhe Zuo1,2, Yingchuo Hu1, Xuan Luo4, Liping Jiang2, Zanxian Xia5,6, Xiaojuan Xiao1, Jing Liu1, Mao Ye7, Meichun Deng1,2,6.   

Abstract

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly throughout the world. Although COVID-19 has a relatively low case severity rate compared to SARS and Middle East Respiratory syndrome it is a major public concern because of its rapid spread and devastating impact on the global economy. Scientists and clinicians are urgently trying to identify drugs to combat the virus with hundreds of clinical trials underway. Current treatments could be divided into two major part: anti-viral agents and host system modulatory agents. On one hand, anti-viral agents focus on virus infection process. Umifenovir blocks virus recognizing host and entry. Remdesivir inhibits virus replication. Chloroquine and hydroxychloroquine involve preventing the whole infection process, including virus transcription and release. On the other hand, host system modulatory agents are associated with regulating the imbalanced inflammatory reaction and biased immune system. Corticosteroid is believed to be commonly used for repressing hyper-inflammation, which is one of the major pathologic mechanisms of COVID-19. Convalescent plasma and neutralizing antibodies provide essential elements for host immune system and create passive immunization. Thrombotic events are at high incidence in COVID-19 patients, thus anti-platelet and anti-coagulation are crucial, as well. Here, we summarized these current or reproposed agents to better understand the mechanisms of agents and give an update of present research situation.
Copyright © 2021 Zuo, Wu, Pan, Zuo, Hu, Luo, Jiang, Xia, Xiao, Liu, Ye and Deng.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; mechanisms; therapeutic agents; treatment

Year:  2021        PMID: 33643033      PMCID: PMC7908061          DOI: 10.3389/fphar.2020.583914

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  254 in total

1.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Authors:  X-T Ye; Y-L Luo; S-C Xia; Q-F Sun; J-G Ding; Y Zhou; W Chen; X-F Wang; W-W Zhang; W-J Du; Z-W Ruan; L Hong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

Review 2.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.

Authors:  Andrea Huwiler; Uwe Zangemeister-Wittke
Journal:  Pharmacol Ther       Date:  2017-11-08       Impact factor: 12.310

3.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Authors:  Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie
Journal:  BMJ       Date:  2020-05-14

4.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Authors:  Sangeun Jeon; Meehyun Ko; Jihye Lee; Inhee Choi; Soo Young Byun; Soonju Park; David Shum; Seungtaek Kim
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era.

Authors:  Rosario Rossi; Francesca Coppi; Marisa Talarico; Giuseppe Boriani
Journal:  Eur J Intern Med       Date:  2020-06-06       Impact factor: 4.487

6.  Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.

Authors:  Maurizio Viecca; Dejan Radovanovic; Giovanni Battista Forleo; Pierachille Santus
Journal:  Pharmacol Res       Date:  2020-05-23       Impact factor: 7.658

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

9.  Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.

Authors:  Naveen Vankadari
Journal:  Int J Antimicrob Agents       Date:  2020-04-28       Impact factor: 5.283

10.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Authors:  Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

View more
  5 in total

1.  Effects of moxibustion for COVID-19 convalescence: A protocol for systematic review and meta-analysis.

Authors:  Yue Zhou; Xiao Yan; Fengjun Ma; Qingchang Xia; Yunping Lu; Wenyuan Li; Shuai Song; Yan Sun; Yuxia Ma; Yuning Ma
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

2.  Acupuncture for nasal congestion in COVID-19: A protocol for systematic review and meta-analysis.

Authors:  Zhibin Dong; Jinyun Guo; Tingting Deng; Jingwen Zhang; Xinwei Lv; Kaixin Zhang; Yuxia Ma; Yuning Ma
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

Review 3.  Pharmacological treatment of COVID-19: an opinion paper.

Authors:  A García-Lledó; J Gómez-Pavón; J González Del Castillo; T Hernández-Sampelayo; M C Martín-Delgado; F J Martín Sánchez; M Martínez-Sellés; J M Molero García; S Moreno Guillén; F J Rodríguez-Artalejo; J Ruiz-Galiana; R Cantón; P De Lucas Ramos; A García-Botella; E Bouza
Journal:  Rev Esp Quimioter       Date:  2021-12-11       Impact factor: 1.553

4.  Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study.

Authors:  Ahmad F Eweas; Hosam-Eldin H Osman; Ibrahim A Naguib; Mohammed A S Abourehab; Ahmed S Abdel-Moneim
Journal:  Curr Issues Mol Biol       Date:  2022-07-04       Impact factor: 2.976

Review 5.  Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19).

Authors:  Ting Wu; Shuntong Kang; Wenyao Peng; Chenzhe Zuo; Yuhao Zhu; Liangyu Pan; Keyun Fu; Yaxian You; Xinyuan Yang; Xuan Luo; Liping Jiang; Meichun Deng
Journal:  Front Med (Lausanne)       Date:  2021-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.